Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

short term income and recurring revenue streams from a successful product launch in the future.

Regulatory strategy

CeNeS preferred strategy is for a partner to be involved in the key decisions regarding regulatory filing strategies both in Europe and in United States. The strategy in the USA is clear. The strong data obtained from the most recent Phase III study validates the proposed product profile of M6G and strengthens CeNeS position with potential North American partners. Registration could be achieved in the USA in 2009 after conducting two Phase III studies to the requirements of the FDA. It is important to note that the quality and robustness of the clinical data produced by the current study significantly reduces the risk for the development of M6G by enabling optimal trial design and the selection of endpoints in the remaining Phase III studies.

In Europe the narrow failure to achieve statistical significance with the second chosen primary endpoint of incidence and severity of nausea (p=0.052 not p<0.050) offers three options:

1) Pursue a filing application in certain European countries with the comprehensive clinical data package that CeNeS has assembled. 2) Further strengthen the European package by conducting an additional European Phase III study which would complete in 2008 with product filing in 2009. 3) Use the USA Phase III trials to support the European application, potentially with a global partner.

CeNeS will continue to discuss the above strategies with regulatory consultants and potential partners.

Neil Clark, Chief Executive of CeNeS commented "The ongoing analysis of the Phase III results further confirms our belief in the excellent potential of M6G as a novel product for post- operative pain. The quality and breadth of the data contained in this large study supports M6G's anticipated product profile.

The potential for reduced anti-emetic drug costs combined with the reduction in medical assi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:8/19/2014)... Avizia, Inc., a leading provider of cutting-edge ... equity financing round led by NextGen Angels along with ... will be used to continue to fuel the rapidly ... Edward Kennedy , CEO and president of Tollgrade ... Leonard Kurtzman , CFO of newBrandAnalytics, who joined the ...
(Date:8/19/2014)... , Aug. 19, 2014  Cardiva Medical, Inc. ... tranches of a $16.5 million Series 3 private equity ... GE Capital. The Company will use the proceeds of ... to expand commercial efforts for its VASCADE® Vascular Closure ... Investing in Series 3 private equity ...
(Date:8/19/2014)... August 19, 2014 Oramed ... clinical-stage pharmaceutical company focused on the development of ... Intellectual Property Department of Spain ... invention, titled "Methods and Compositions for Oral Administrations ... Oramed Pharmaceuticals is a technology pioneer in ...
Breaking Medicine Technology:Avizia Closes Funding Round 2Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2Oramed Granted Patent in Spain for Oral Administration of Insulin 2Oramed Granted Patent in Spain for Oral Administration of Insulin 3
... May 2, 2011 EMBEDDED SYSTEMS CONFERENCE -- Samplify ... availability of Prism FP ™ , the first compression ... floating point data types.   "Distribution of ... of thousands of computing nodes poses a challenge in ...
... May 2, 2011 Prometheus Laboratories Inc., a specialty ... signed an exclusive agreement with WILEX AG for commercialization ... is a Phase III product candidate for adjuvant use ... Under the terms of the agreement, WILEX will receive ...
Cached Medicine Technology:Samplify Systems Announces Availability of Prism FP Floating Point Compression 2Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX® 2Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX® 3
(Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... Conference will get a sneak peak at Los Angeles’ ... along with a tour of a blossoming 1.5-acre high ... visit to a shipping container farm in the L.A. ... the wide-ranging diversity of sustainable urban agriculture, will kick ...
(Date:8/20/2014)... 2014 August is Children’s Eye Health ... educated about eye health and safety for their children ... eye condition that must be checked for, according to ... of Water radio show, is pediatric dry eye. With ... dry eye is becoming a very real concern to ...
(Date:8/20/2014)... OXNARD, CA (PRWEB) August 20, 2014 ... Saj Jivraj, founder of the Anacapa Dental Art Institute, ... month. , Dr. Jivraj will be speaking on ... and Laboratory Aspects of Graft Less Solutions” at 12:40 ... Conference Centre in Vancouver, British Columbia, Canada. , “The ...
(Date:8/20/2014)... Inc. Magazine recently named Etransmedia ... annual Inc. 500|5000, an exclusive ranking of the ... most comprehensive look at the most important segment ... Yelp, Pandora, Timberland, Dell, Domino’s Pizza, LinkedIn, Zillow ... as members of the Inc. 500|5000. , “We ...
(Date:8/20/2014)... “Have you recently been involved in an ... injury lawyer serving the greater Seattle area. “Are you still ... then keep reading . , In a recently released article, ... auto accident can use to see if they may qualify ... injury insurance claim will allow an individual to receive medical ...
Breaking Medicine News(10 mins):Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 2Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 3Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3Health News:Internationally Known Oxnard Dentist to Speak at Conference in Vancouver 2Health News:Internationally Known Oxnard Dentist to Speak at Conference in Vancouver 3Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2
... 5 Chiltern, a leading global research,organization, is proud ... Clinical Researcher of the Year ceremony, including the coveted,Clinical ... following awards: Gold: Clinical Department of the Year ... Project Manager category Gold: Kara Tanabe in Clinical ...
... evidence shows that surgery may effectively cure Type 2 diabetes -- ... is treated, but that introduces a new way of thinking about ... to the February issue of Diabetes Care by a leading expert ... small bowel as the possible site of critical mechanisms for the ...
... 5 A protein that governs,development of human ... spread of malignant melanoma, the deadliest skin cancer, ... the transformation of skin pigment cells or melanocytes, ... and a median survival of less than 7.5 ...
... INDIANAPOLIS, March 5 Anthem National Accounts today,announced ... to address,the needs of early retirees -- a ... of products is designed to meet the needs ... and provide affordable,access to medical coverage while helping ...
... to protect their children from exposure to secondhand smoke, ... Hopkins Bloomberg School of Public Health. Exposure to secondhand ... for numerous illnesses and premature death. The household study, ... parents who smoked reported smoking around their children. Measurements ...
... Kids Pledges up to ... Type 1 Diabetes Research, ATLANTA, March 5 White Hat ... announced today the launch of a,three- year partnership with the Juvenile ... 1,diabetes research., As part of this milestone relationship, White Hat ...
Cached Medicine News:Health News:Chiltern Wins Top Prize 2Health News:Type 2 diabetes may be caused by intestinal dysfunction 2Health News:Type 2 diabetes may be caused by intestinal dysfunction 3Health News:Type 2 diabetes may be caused by intestinal dysfunction 4Health News:Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells 2Health News:Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells 3Health News:Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells 4Health News:Anthem National Accounts Introduces New Products for Large Employers' Early Retirees 2Health News:Anthem National Accounts Introduces New Products for Large Employers' Early Retirees 3Health News:Secondhand smoke a risk for children worldwide 2Health News:White Hat Brands, Juvenile Diabetes Research Foundation Offer the 'Juice' on New Partnership 2Health News:White Hat Brands, Juvenile Diabetes Research Foundation Offer the 'Juice' on New Partnership 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: